Search
for

    Research

    5 / 1000+ results

    Community Join

    5 / 137 results

      community Why is everyone still arguing about PP405 when clascoterone is already heading toward regulatory submission?

       46 upvotes 1 month ago
      Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.

      community The ANSM is trying to ban Finasteride

      in Research/Science  110 upvotes 1 year ago
      France is considering reviewing finasteride and dutasteride due to concerns about their safety, but a ban in the EU is unlikely due to regulatory hurdles. Many users express frustration over the potential ban, emphasizing the effectiveness of finasteride for hair loss and criticizing the influence of anecdotal evidence on public health policy.

      community Why doesn't phase 3 of PP405 start straight away?

      in Chat  14 upvotes 8 months ago
      Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

      community Petition Alert: Let's Get PP405 Phase 3 Trials in Germany by 2026!

       55 upvotes 1 year ago
      A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

    Learn

    3 / 801 results

      learn Cyproterone

      • Is cyproterone safe to use during gender transition? Regulators and a large French cohort study link higher-dose, long-term cyproterone acetate to meningioma, and its label also lists liver-enzyme and mood effects — so it is not a drug anyone should call safe in the abstract, and its use in gender-affirming care is a prescriber's decision with monitoring.

      learn Osteopontin

      signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss